Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study
Open Access
- 1 January 2017
- journal article
- research article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 173, 56-63
- https://doi.org/10.1016/j.ajo.2016.09.029
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic RetinopathyDiabetes Care, 2014
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular EdemaOphthalmology, 2013
- ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2013
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year ResultsOphthalmology, 2012
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Angiogenic Pathways in Diabetic RetinopathyThe New England Journal of Medicine, 2005
- Photocoagulation Therapy for Diabetic Eye DiseaseJAMA, 1985
- Photocoagulation for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 1985